News

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox
NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...
Investornewsbreaks Nanoviricides (NYSE American: NNVC) Finalizes Adaptive Trial Design For Mpox Drug NV-387
NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage innovator in broad-spectrum antivirals, announced near-finalization of its adaptive clin ...
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...
Nanoviricides (NNVC) Accelerates Mpox Drug Development, Citing Strong Business And Public Health Case
NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide class of drug candidates ...
Centre Daily Times27d
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum ...
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides’ Dr. Diwan ...
Morningstar27d
With Rising Variants of COVID and Bird Flu, the Single ... - Morningstar
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan ...
wacotrib15d
There is a Strong Business Case for Phase II Clinical Program for ...
NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal ...